Login to Your Account



Clinic Roundup


Thursday, May 12, 2011
NanoBio Corp., of Ann Arbor, Mich., began two Phase III trials of NB-001 for cold sores, as part of its 2009 licensing agreement with GlaxoSmithKline Consumer Healthcare, a division of GlaxoSmithKline plc, of London. The trials will enroll a total of 1,700 subjects at 72 clinical sites, and are expected to conclude in 2012.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription